Reuters benchmarking versus UK NHS payouts showed ~33% of sampled TrumpRx-listed drugs were cheaper in the UK, with 67%–82% ...

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...

One key failure mechanism is the logistic implementation for the DCT trials. A lot of times, when you go to a global trial, there's a lot of logistic management for DCT. Let's say you must ship the ...

Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive ...

In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two ...

Founder, Infinitus touches on the approach to human oversight in an effort to build trust in autonomous patient access workflows by keeping humans and AI in a continuous feedback loop. In a ...

While the AI story continues to unfold across the pharma industry, one aspect may be causing more issues than solutions. Dave Rusher, CCO at Aravo, joined Pharmaceutical Executive ...

President of Patient Affordability, Paysign, mentions how Paysign's approach to measuring copay program value is in an effort to move beyond simple redemption counts toward a more complete picture of ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...

Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling ...

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...